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Objective: No treatment is recommended for routine maintenance tocolysis after an arrested preterm
birth. Our present study aimed to evaluate the effect of progesterone and nifedipine as maintenance
tocolysis therapy after an arrested preterm birth.
Materials and Methods: For relevant studies, we systematically searched the literature in databases of
PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane
Library. Only randomized controlled trials were included.
Results: Nine trials were included in our review. Nifedipine and progesterone were used for maintenance
tocolysis. Compared to placebo treatment or no treatment, maintenance tocolysis with progesterone
could signiﬁcantly prolong the delivery gestational weeks [standard mean difference (SMD) 1.64; 95%
conﬁdence interval (CI), 1.21, 2.07; p < 0.00001], reduce the proportion of patients with delivery before
37 weeks (risk ratio 0.63; 95% CI, 0.47, 0.83; p ¼ 0.001), and increase the birth weight (SMD 317.71; 95%
CI, 174.89, 460.53; p < 0.0001). However, no such beneﬁts were observed after maintenance tocolysis
with nifedipine. Both nifedipine and progesterone had no signiﬁcant inﬂuences on the following out-
comes: neonatal intensive care unit stay, proportion of neonatal intensive care unit admission, neonatal
mortality, and incidence of respiratory distress syndrome.
Conclusion: Our results with maintenance tocolysis with progesterone may be useful for patients who
had an episode of threatened preterm labor successfully treated with acute tocolytic therapy.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
A common cause of neonatal morbidity andmortality is preterm
birth. Nearly 75% of perinatal deaths occur in infants born before
37 weeks' gestation [1,2].
After arrested preterm labor with acute tocolysis, maintenance
tocolysis should be continued with the goals of prolonging gesta-
tion and improving neonatal outcome. There are several reasons to
consider maintenance tocolysis. First, perinatal morbidity and
mortality are inversely related to gestational age [3], therefore
delaying delivery may improve perinatal outcome. Second, after anand Gynecology, First Afﬁli-
yi Road Number 1, Yuzhong
bstetrics & Gynecology. Published bepisode of preterm labor, the stimulus for preterm labor may
remain and the patient remains at increased risk for preterm de-
livery. Prostaglandins, which are increased with contractions, can
upregulate oxytocin receptors and potentially increase the risk for
preterm delivery [4].
However, the effectiveness of maintenance tocolysis is unclear.
Our present study aimed to evaluate the effect of progesterone and
nifedipine as the maintenance tocolysis therapy after arrested
preterm birth.
Methods
Eligibility criteria
Randomized controlled trials that enrolled participants who had
been in active preterm labor, as deﬁned by contractions with cer-
vical change, and had their preterm labor successfully arrestedy Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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one or nifedipine were administered.
The following outcomes were measured: delivery gestational
weeks, pregnancy prolongation, and proportion of patients with
delivery at <37 weeks, birth weight, proportion of neonatal
intensive care unit admissions, neonatal mortality, and incidence of
respiratory distress syndrome.
Literature search
Studies were identiﬁed by searching electronic databases and
scanning the reference lists of the articles. This search was applied
to PubMed (years 1980e2014), and adapted for Embase (years
1980e2014). Cochrane databases were also reviewed. The last
search was performed on December 31, 2014.
Search strategy and study selection
Keywords combined with Medical Subject Headings (MESH)
terms such as “nifedipine” and “progesterone” were used for the
search. Eligibility assessment was performed independently in an
unblended standardized manner by two reviewers. Disagreements
between reviewers were resolved by consensus. One review author
extracted the data from the included studies and the second author
checked the extracted data. Information on the characteristics of a
trial was extracted from each included trial.
Risk of bias in individual studies
The risk of bias assessment was performed independently by
two investigators. Disagreements were resolved by discussion.
The risk of bias was assessed, as described in the Cochrane
handbook [5], by recording the methods used to generate the
randomization schedule and conceal allocation; by whether
blinding was implemented for participants, staff, and outcome
assessment; by the proportion of patients who completed follow
up; and by whether there was evidence of selective reporting of
outcomes.
Statistics
The risk ratio (RR) with 95% conﬁdence interval (CI) was
calculated for dichotomous variables. For continuous outcomes,
we pooled the study results using the standard mean difference
(SMD). The SMD calculation requires a mean value and standard
deviation for each group. Differences in the means were signiﬁ-
cant at p < 0.05. Heterogeneity between studies was assessed
using the I2 statistic with a cut-off value of 50%, and the c2 test
with a p < 0.10 was used to deﬁne a signiﬁcant degree of het-
erogeneity [6].
Results
Based on the search strategy (Figure 1), 10 trials were
included in our study [7e16]. Of these, ﬁve trials evaluated the
effect of nifedipine for maintenance tocolysis after arrested
preterm labor, compared to a placebo treatment or no treatment
[10,13e16]. Another four studies evaluated the effect of proges-
terone for maintenance tocolysis after arrested preterm labor,
compared to placebo or no treatment [7e9,11]. The remaining
trial evaluated the relative effect of progesterone versus as
maintenance tocolysis after arrested preterm labor [12]. The
main characteristics are presented in Table 1. Most included trials
were of high or moderate methodological quality.Meta-analysis
The items for delivery outcomes and neonatal outcomes reported
in every trial were somewhat different. The outcomes that were
mostly reported were therefore chosen for quantitative analyses.
Gestational weeks at delivery and pregnancy prolongation (in days)
The outcome of gestational weeks at delivery was reported in all
included trials. The overall pooled results from the meta-analysis
demonstrated that, compared to placebo or no treatment, main-
tenance tocolysis therapy with progesterone could signiﬁcantly
prolong the number of gestational weeks at delivery (SMD, 1.64;
95% CI, 1.21, 2.07; p < 0.00001; Figure 2A). In addition, progesterone
was more effective than nifedipine in maintenance tocolysis ther-
apy after arrested preterm birth (SMD, 2.60; 95% CI, 1.71, 3.49;
p < 0.00001; Figure 2B). However, no signiﬁcant beneﬁt was
observed after maintenance tocolysis therapy with nifedipine,
compared to placebo or no treatment (SMD, 0.31; 95% CI, -0.60,
1.22; p ¼ 0.50; Figure 2C).
The outcome of pregnancy prolongation was also reported in all
included trials. Similar pooled results were obtained after meta-
analyses, as shown in Figure 2. Patients in the progesterone group
had a longer latency until delivery than patients in the placebo
group (SMD, 11.05; 95% CI, 4.76, 17.33; p ¼ 0.0006; Figure 3A) or
patients in the nifedipine group (SMD, 23.50; 95% CI, 18.40, 28.60;
p < 0.00001; Figure 3B). However, there was no signiﬁcant differ-
ence between the nifedipine group and the placebo group (SMD,
2.21; 95% CI, -3.63, 8.05; p ¼ 0.46; Figure 3C).
The proportion of patients with delivery at <37 weeks
The outcome of the proportion of patients with delivery at
<37 weeks was reported in seven trials. The proportion of patients
with delivery at <37 weeks was 41% in the progesterone group, 64%
in the placebo/no treatment group, and 67% in the nifedipine group.
Signiﬁcantly fewer patients in the progesterone group delivered
after 37 weeks, compared to the placebo or no treatment groups
(RR, 0.63; 95% CI, 0.47, 0.83; p ¼ 0.001; Figure 4A), and nifedipine
group (RR, 0.43; 95% CI, 0.30, 0.62; p < 0.00001; Figure 4B). How-
ever, there was no difference between the nifedipine group and the
placebo or no treatment group in the proportion of patients with
delivery at <37 weeks (RR, 0.97; 95% CI, 0.87, 1.09; p ¼ 0.64;
Figure 4C).
Neonatal outcomes
The outcome of birth weight was reported in nine trials. The
overall pooled results demonstrated that maintenance tocolysis
therapy with progesterone could signiﬁcantly improve birth
weight, compared to placebo or no treatment. (SMD, 317.71; 95% CI,
174.89, 460.53; p < 0.00001; Figure 5A). However, there was no
signiﬁcant difference between the nifedipine group and the pla-
cebo group (SMD, 5.58; 95% CI, -103.28,114.43; p¼ 0.92; Figure 5B).
The outcomes of the proportion of neonatal intensive care unit
admissions, neonatal intensive care unit stay, mortality rate, and
incidence of respiratory distress syndrome were not signiﬁcantly
different, based on the comparison of progesterone versus placebo
or no treatment, and the comparison of nifedipine versus placebo
or no treatment.
Discussion
Our present meta-analysis systematically reviewed mainte-
nance tocolysis therapy with progesterone and nifedipine after
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Figure 1. Flow chart of the study selection.
Table 1
The main characteristics of the included trials.
Study Country Mean age Age (mean) Gestation weeks Treatment
intervention
Control
intervention
Carr 1999 [10] USA 37/37 22.7/22.8 24e34 Nifedipine No treatment
Sayin 2004 [16] Turkey 37/36 26.6/27.3 Not reported Nifedipine No treatment
Lyell 2008 [13] USA 33/35 28.4/28.1 24e34 Nifedipine Placebo
Roos 2013 [15] Netherlands 201/205 30.2/30.2 26e32 Nifedipine Placebo
Parry 2014 [14] New Zealand 29/31 29.0/29.7 24e34 Nifedipine Placebo
Kamat 2014 [12] India 49/51 Not reported <37 Progesterone Nifedipine
Borna 2008 [9] Iran 37/33 26.1/25.5 24e34 Progesterone No treatment
Arikan 2011 [8] Turkey 43/40 Not reported 24e34 Progesterone No treatment
Areia 2013 [7] Portugal 26/26 30.1/28.38 24e34 Progesterone No treatment or placebo
Choudhary 2014 [11] India 45/45 24.1/23.7 24e34 Progesterone Placebo
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after an initial episode of preterm labor is controversial. Our results
altogether demonstrated that maintenance tocolysis with proges-
teronemay be useful for patients who had an episode of threatened
preterm labor that was successfully treated by acute tocolytic
therapy; however, there are no beneﬁts in maintenance tocolysis
therapy with nifedipine.
Progesterone has been studied extensively for the prevention of
preterm labor in high-risk patients such as womenwith a history of
preterm labor and women with a short cervix in the current
pregnancy [17,18]. However, the mechanism of action of proges-
terone in prolonging pregnancy is not well known. Until recently,several trials evaluating the effect of progesterone for maintenance
tocolysis treatment after arrested preterm labor had been pub-
lished [7e9,11]. Vaginal progesterone was used in three of these
trials [7e9], and oral micronized progesterone was administered in
the remaining study [11]. The dosage of progesterone was 200 mg
or 400 mg. From these studies, we found that vaginal and oral
progesterone were both effective in prolonging the latency period
and increasing the birth weight of neonates, and that 200 mg and
400 mg of progesterone were effective. Furthermore, the use of
progesterone did not increase the incidence rate of adverse events.
We provided robust evidence that progesterone was effective for
maintenance tocolysis treatment after arrested preterm labor. In
Figure 2. Meta-analysis for the outcome of the gestational age at delivery (weeks). (A) Progesterone versus placebo or no treatment. (B) Progesterone versus nifedipine. (C)
Nifedipine versus placebo or no treatment. CI ¼ conﬁdence interval; IV ¼ inverse variance; SD ¼ standard deviation.
Figure 3. Meta-analysis for the outcome of pregnancy prolongation (days). (A) Progesterone versus placebo or no treatment. (B) Progesterone versus nifedipine. (C) Nifedipine
versus placebo or no treatment. CI ¼ conﬁdence interval; IV ¼ inverse variance; SD ¼ standard deviation.
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one with nifedipine for maintenance tocolysis after arrested pre-
term labor, with results in favor of progesterone. Several relevant
reviews have recently been published. In 2012, Haas et al [19] found
that prostaglandin inhibitors and calcium channel blockers had thehighest probability of delaying delivery and improving neonatal
and maternal outcomes. In 2015, Suhag et al [20] in a meta-analysis
of randomized controlled trials evaluated the efﬁcacy of mainte-
nance tocolysis with vaginal progesterone, compared to the control
group (i.e., placebo or no treatment) in singleton gestations with
Figure 4. Meta-analysis for the outcome of the proportion of patients with delivery at <37 weeks. (A) Progesterone versus placebo or no treatment. (B) Progesterone versus
nifedipine. (C) Nifedipine versus placebo or no treatment. CI ¼ conﬁdence interval; IV ¼ inverse variance; SD ¼ standard deviation.
Figure 5. Meta-analysis for the outcome of birth weight. (A) Progesterone versus placebo or no treatment. (B) Nifedipine versus placebo or no treatment. CI ¼ conﬁdence interval;
IV ¼ inverse variance; SD ¼ standard deviation.
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evaluated the efﬁcacy of maintenance tocolysis with vaginal pro-
gesterone and nifedipine. Another review [21] evaluated the efﬁ-
cacy of maintenance tocolysis with 17-alpha-hydroxyprogesterone
caproate, which suggested that 17-alpha-hydroxyprogesterone
caproate for maintenance tocolysis is associated with a signiﬁcant
prolongation of pregnancy, and signiﬁcantly higher birth weight.
Further study could evaluate the relative efﬁcacy of maintenance
tocolysis with progesterone versus 17-alpha-hydroxyprogesterone
caproate.Nifedipine, a slow-release calcium channel blocker, is an alter-
native tocolytic agent. Maintenance nifedipine tocolysis is a com-
mon practice in the United States. In a survey to which 46% of
Society for MaternaleFetal Medicine members responded, 29% of
members reported that they would recommend maintenance
tocolysis, and of these, 79% reported that nifedipine was their ﬁrst-
line maintenance tocolytic [19]. One included trial [20] demon-
strated that oral maintenance tocolysis with nifedipine could
signiﬁcantly prolong gestational age. However, other included trials
did not observe the same results [10,13e15], and the pooled results
M.-X. Ding et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 399e404404found that maintenance nifedipine tocolysis did not provide any
beneﬁt for pregnancy prolongation or the outcomes of the neo-
nates. Our present study found that maintenance tocolysis with
progesterone was effective for prolonging pregnancy and
improving the birth weight of neonates for patients who had an
episode of threatened preterm labor successfully treatedwith acute
tocolytic therapy, whereas maintenance tocolysis therapy with
nifedipine did not have the expected efﬁcacy of pregnancy
prolongation.
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